Corps Capital Advisors’s AbbVie ABBV Stock Holding History

Corps Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.47M	Sell	5,633 -15	-0.3%	-$3.84K	1.14%	25
2026 Q2	$1.42M	Sell	5,648 -44	-0.8%	-$9.47K	1.15%	26
2026 Q1	$1.24M	Sell	5,692 -10	-0.2%	-$2.22K	1.07%	26
2025 Q4	$1.3M	Buy	5,702 +1,360	+31%	+$310K	1.35%	20
2025 Q3	$1.01M	Hold	4,342	–	–	1.52%	20
2025 Q2	$806K	Sell	4,342 -4,803	-53%	-$893K	1.3%	24
2025 Q1	$1.92M	Hold	9,145	–	–	2.02%	12
2024 Q4	$1.63M	Buy	+9,145	New	+$1.68M	1.65%	19

Other funds holding ABBV

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Corps Capital Advisors's ABBV Position: Q3 2026 in Review

Corps Capital Advisors reduced its AbbVie (ABBV) stake by 0.27% in Q3 2026, selling an estimated $3.84K and leaving 5,633 shares worth $1.47M. The position accounts for 1.14% of the portfolio, ranked #25.

Corps Capital Advisors first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.92M in Q1 2025. 3,064 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Corps Capital Advisors held 5,633 shares of AbbVie worth $1.47M as of Q3 2026.
Corps Capital Advisors sold 15 AbbVie shares in Q3 2026, an estimated $3.84K.
AbbVie made up 1.14% of Corps Capital Advisors's portfolio in Q3 2026, its #25 holding.
Corps Capital Advisors first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
Corps Capital Advisors's AbbVie position peaked at $1.92M in Q1 2025.
3,064 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Corps Capital Advisors's 13F filing for Q3 2026, filed 5 Nov 2026.